top of page

Emylif is competitively priced versus the equivalent dose of riluzole oral suspension

Price icon.png

-10%

£

1

Emylif (8).png

Emylif is currently priced at a cost £168/pack (56 tabs), offering a 10% reduction in annual drug treatment price from Teglutik (riluzole oral suspension)

1

1. NHS Drug Tariff Accessed January 2023. Drug Tariff Category M, prices may vary. 365 days treatment. Please visit https://bnf.nice.org.uk/drugs/riluzole/medicinal -forms/ for the latest prices

Comparative NHS costs of riluzole formulations

Emylif (23).png

NHS Drug Tariff accessed January 2023. Drug Tariff Category M, prices may vary. 365 days treatment. Please visit https://bnf.nice.org.uk/drugs/riluzole/medicinal -forms/ for the latest prices.

As an example, ALS patient prescribed Emylif that was taking oral suspension this would represent an annual saving of £243.33.

If Emylif use is expanded beyond the current typical use of oral solution where a patient first begins to develop dysphasia, this would likely lead to an increase of £2,080.11 per year.

This does not include additional costs associated with additional devices, time, resource for manipulation and administration of riluzole formulations. Consideration also needs to be made of the treatment pathway and quality of life benefits, and avoidance of potential issues associated with crushing tablets, enteral or bolus administration.

Pricing

Effects on how services and non-medical costs are delivered to patients

Advantages of switching from crushing tablets for oral administration to Emylif

  • No tablet crusher required, or necessary competence to perform crushing from patient, healthcare professional and/or carer

  • No mixing with soft food/puree

  • No unlicensed use of administration

Emylif (10).png

Advantages of switching from crushing tablets for enteral tube administration to Emylif

  • No tablet crusher required, or necessary competence to perform crushing from patient, healthcare professional and/or carer

  • No dispersion in water (or necessary competence regarding volumes from patient, healthcare professional and/or carer, or concerns over time left in dispersion prior to administration)

  • No requirement to flush enteral tube pre-administration, or the necessary competence to perform flushing from patient, healthcare professional, patient and/or carer

  • No requirement to measure and administer the required dose with a dosing syringe

  • No risk of blocking enteral tubes

  • No requirement to flush enteral tube post administration (or the necessary competence to perform flushing from patient healthcare professional and/or carer)

  • No unlicensed use of administration

Emylif (9).png

Advantages of switching from oral suspension to Emylif

  • No requirement to manually shake a bottle for at least 30 seconds pre-dose measurement

  • No requirement to flush enteral tube pre-administration (or the necessary competence to perform flushing from patient, healthcare professional, patient and/or carer)

  • No requirement to measure and administer the required dose with a dosing syringe

  • No requirement to flush enteral tube post administration (or the necessary competence to
    perform flushing from patient healthcare professional and/or carer)

Service cost impact
Formulary support

Formulary application support

Emylif (11).png

We are happy to support you in your application for adding Emylif to your formulary.

 

Please fill out our contact form or contact your Account Manager directly at the link below.

References

NHS Drug Tariff Accessed January 2023. Drug Tariff Category M, prices may vary. 365 days treatment. Please visit https://bnf.nice.org.uk/drugs/riluzole/medicinal-forms/ for the latest prices

GB_ROF_032

April 2023

Adverse event reporting
bottom of page